Federal contract award
75A50120C00169
CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $73.9M |
| Current contract value | $73.9M |
| Potential contract value / ceiling | $109.8M |
| Start date | Sep 28, 2020 |
| Current end date | Dec 31, 2026 |
| Potential end date | Jan 1, 2027 |
| Latest award activity | Sep 16, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 16, 2025 | P00009 | $18.0M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1. ADD $14,773,583.00 OF SUPPLEMENTAL FUNDING TO CLIN 0002. 2. ADD $3,226,417.00 OF SUPPLEMENTAL FUNDING TO CLIN 0003. |
| Feb 21, 2025 | P00008 | $6.9M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO: 1.SUPPLEMENTALLY FUND CLIN 0003. 2.UPDATE KEY PERSONNEL. 3.EXTEND PERIOD OF PERFORMANCE FOR CLINS 0002 AND 0003 TO END 12/31/2026. |
| Jan 19, 2024 | P00007 | $23.9M | THE PURPOSES OF THIS MODIFICATION ARE TO 1. EXERCISE OPTION PERIOD 1 CLIN 0002 WITH A PERIOD OF PERFORMANCE OF JANUARY 19, 2024 TO SEPTEMBER 30, 2025. 2. INCREASE THE INDIRECT RATE CAPS AS A RESULT OF THIS MODIFICATION: 1. FUNDING IN THE AM |
| Feb 15, 2023 | P00006 | $7.8M | THE PURPOSES OF THIS BILATERAL MODIFICATION ARE TO: 1) ADD $7,809,935.00 UNDER THE BASE PERIOD CLIN 0001 WITH A PERIOD OF PERFORMANCE OF SEPTEMBER 28, 2022 ? MARCH 31 2023; 2) EXTEND THE PERIOD OF PERFORMANCE TO SEPTEMBER 20, 2024; 3) AND UPDATE |
| Sep 27, 2022 | P00005 | $0 | THE PURPOSE OF THIS NO COST, BILATERAL MODIFICATION IS TO: A.) UPDATE ARTICLE B.2, BASE PERIOD TO UPDATE THE POP OF CLIN 0001. B.) THE PERIOD OF PERFORMANCE FOR CLIN 0001 (BASE PERIOD) IS EXTENDED FROM 09/28/2020 - 09/27/2022 TO 09/28/2020 - 03 |
| Jun 22, 2022 | P00004 | $6.2M | ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI. |
| Nov 2, 2021 | P00003 | $0 | ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI. |
| Sep 9, 2021 | P00002 | $0 | ADVANCE THE DEVELOPMENT OF CRPHAGE AS A CRISPR-ENGINEERED PRECISION ANTIBACTERIAL OF URINARY TRACT INFECTIONS CAUSED BY E. COLI. |
| Mar 4, 2021 | P00001 | $0 | ADMINISTRATIVE MOD TO CHANGE COR |
| Sep 28, 2020 | 0 | $11.0M | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
75/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 75/100. Available recorded signals: 70 points.
- Contract end 2027-01-01 (68 days from calculation)
- +35 points
- 121 historical awards in this buyer and category group
- +15 points
- 10 recorded award transactions
- +10 points
- Latest award action: 2025-09-16
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.